Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Parks

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
AIDS (London, England)|December 15, 2017
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone healthGrace A McComsey, Sergio Lupo, David Parks, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2026
SpikeLab: Agentic tools for spike data analysisTjitse Van der Molen, Luka Cheney, Kamran Hussain, et al.
Immunologic Research|May 15, 2014
AutoGate: automating analysis of flow cytometry dataStephen Meehan, Guenther Walther, Wayne Moore, et al.
The Lancet. HIV|July 17, 2019
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studiesMichael Aboud, Chloe Orkin, Daniel Podzamczer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 18, 2020
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical TrialsJean van Wyk, Chloe Orkin, Rafael Rubio, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|November 26, 2009
Data File Standard for Flow Cytometry, version FCS 3.1Josef Spidlen, Wayne Moore, David Parks, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
AIDS (London, England)|December 15, 2017
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone healthGrace A McComsey, Sergio Lupo, David Parks, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2026
SpikeLab: Agentic tools for spike data analysisTjitse Van der Molen, Luka Cheney, Kamran Hussain, et al.
Immunologic Research|May 15, 2014
AutoGate: automating analysis of flow cytometry dataStephen Meehan, Guenther Walther, Wayne Moore, et al.
The Lancet. HIV|July 17, 2019
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studiesMichael Aboud, Chloe Orkin, Daniel Podzamczer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 18, 2020
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical TrialsJean van Wyk, Chloe Orkin, Rafael Rubio, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|November 26, 2009
Data File Standard for Flow Cytometry, version FCS 3.1Josef Spidlen, Wayne Moore, David Parks, et al.
Pageof 2